imatinib mesylate has been researched along with Soft Tissue Neoplasms in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (45.45) | 29.6817 |
| 2010's | 9 (40.91) | 24.3611 |
| 2020's | 3 (13.64) | 2.80 |
| Authors | Studies |
|---|---|
| Belgioia, L; Bertulli, R; Buscaglia, M; Catalano, F; Comandini, D; Grassi, M; Rebuzzi, SE; Satragno, C | 1 |
| Blay, JY; Lebellec, L; Penel, N; Robin, YM | 1 |
| Callegaro, D; Gladdy, R; Gronchi, A; Keung, EZ; Kim, T; Le Pechoux, C; Martin-Broto, J; Raut, CP; Swallow, C | 1 |
| Dębiec-Rychter, M; Jagielska, B; Klimczak, A; Pieńkowska-Grela, B; Rutkowski, P; Świtaj, T; Wągrodzki, M; Ługowska, I | 1 |
| Appay, R; Aubert, S; Bouvier, C; Delteil, C; Macagno, N; Magis, Q; Malissen, N; Richard, MA | 1 |
| Wang, J; Yu, L | 1 |
| Bauer, S; Dimitrakopoulou-Strauss, A; Gruenwald, V; Haller, F; Hohenberger, P; Kasper, B; Limprecht, R; Pilz, L; Rauch, G; Reichardt, P; Sommer, M | 1 |
| Blay, JY; Debiec-Rychter, M; Gelderblom, H; Guchelaar, HJ; Judson, I; Peng, B; van Erp, N; van Glabbeke, M; Van Oosterom, A; Verweij, J | 1 |
| Bovée, JV; Gelderblom, H; Hogendoorn, PC; Kroep, JR; van der Molen, AJ | 1 |
| Emile, JF | 1 |
| Delank, S; Eich, H; Wendtner, CM | 1 |
| Bertz-Lepel, J; Pink, D; Reichardt, P | 1 |
| Allison, K; Jones, AP | 1 |
| Lewis, VO; Ravi, V; Wang, WL | 1 |
| Cho, JH; Hur, M; Kim, WS; Ko, YS; Lee, MH; Moon, HW; Yun, YM | 1 |
| Baty, V; Blay, JY; Boukovinas, I; Le Cesne, A; Michallet, V; Ranchere, D; Ray-Coquard, I; Thiesse, P | 1 |
| A'Hern, R; Burton, P; Hayes, AJ; Koban, MU; Mostyn-Jones, A; Thomas, JM | 1 |
| Fernberg, JO; Hall, KS | 1 |
| Verweij, J | 1 |
| Corless, CL; Heinrich, MC | 1 |
| Chuman, H | 1 |
| Patel, SR | 1 |
13 review(s) available for imatinib mesylate and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Overview of « druggable » alterations by histological subtypes of sarcomas and connective tissue intermediate malignancies.
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Neoplasms, Connective Tissue; Sarcoma; Soft Tissue Neoplasms | 2020 |
Strategies for care of patients with gastrointestinal stromal tumor or soft tissue sarcoma during COVID-19 pandemic: A guide for surgical oncologists.
Topics: COVID-19; Gastrointestinal Stromal Tumors; Health Resources; Humans; Imatinib Mesylate; Oncologists; Practice Guidelines as Topic; SARS-CoV-2; Soft Tissue Neoplasms; Surgical Oncology | 2021 |
Extra-abdominal subcutaneous metastasis of a gastrointestinal stromal tumor: report of a case and a review of the literature.
Topics: Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Bone Neoplasms; Carcinoma; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Indoles; Liver Neoplasms; Piperazines; Pyrimidines; Pyrroles; Soft Tissue Neoplasms; Subcutaneous Fat; Sunitinib | 2009 |
[Targeted therapies in soft-tissue and visceral sarcomas].
Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Drug Delivery Systems; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Proteins; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Viscera | 2009 |
[Multimodality therapy concepts for soft tissue sarcomas].
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Cross-Sectional Studies; Gastrointestinal Stromal Tumors; Humans; Hyperthermia, Induced; Imatinib Mesylate; Indoles; Neoadjuvant Therapy; Palliative Care; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Radiotherapy, Adjuvant; Sarcoma; Soft Tissue Neoplasms; Sunitinib | 2010 |
[Systemic therapy of soft tissue sarcomas].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Drug Delivery Systems; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Survival Rate | 2011 |
Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis.
Topics: Antineoplastic Agents; Benzamides; Giant Cell Tumors; Humans; Imatinib Mesylate; Indoles; Macrophage Colony-Stimulating Factor; Macrophages; Piperazines; Pyrimidines; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Soft Tissue Neoplasms; Sunitinib; Synovial Membrane; Synovitis, Pigmented Villonodular; Tendons | 2011 |
Therapy-related acute leukemia with mixed phenotype and t(9;22)(q32;q11.2): a case report and review of the literature.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Back; Benzamides; Bone Marrow; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cytarabine; Endometrial Neoplasms; Female; Gene Rearrangement; Genes, abl; Humans; Idarubicin; Imatinib Mesylate; Immunophenotyping; Induction Chemotherapy; Karyotyping; Leukemia, Myeloid, Acute; Leukemic Infiltration; Middle Aged; Neoplasms, Second Primary; Piperazines; Pyrimidines; Remission Induction; Soft Tissue Neoplasms; Submandibular Gland Neoplasms; Translocation, Genetic | 2012 |
[Gastro-intestinal stromal tumors: news and comments].
Topics: Age Factors; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Mutation; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Soft Tissue Neoplasms | 2003 |
Chemotherapy in soft tissue sarcoma. The Scandinavian Sarcoma Group experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemotherapy, Adjuvant; Disease-Free Survival; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Meta-Analysis as Topic; Piperazines; Prospective Studies; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Registries; Remission Induction; Sarcoma; Scandinavian and Nordic Countries; Soft Tissue Neoplasms | 2004 |
KIT and PDGF as targets.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Piperazines; Platelet-Derived Growth Factor; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Sarcoma; Soft Tissue Neoplasms | 2004 |
Targeting mutant kinases in gastrointestinal stromal tumors: a paradigm for molecular therapy of other sarcomas.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Mutation; Piperazines; Platelet-Derived Growth Factor; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Sarcoma; Soft Tissue Neoplasms | 2004 |
[Current strategy of chemotherapy for reflactory bone and soft tissue sarcomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Imatinib Mesylate; Lung Neoplasms; Piperazines; Prognosis; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Soft Tissue Neoplasms; Survival Rate; Taxoids | 2004 |
1 trial(s) available for imatinib mesylate and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG).
Topics: Abdominal Neoplasms; Abdominal Wall; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Extremities; Female; Fibromatosis, Aggressive; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasms, Multiple Primary; Positron-Emission Tomography; Pyrimidines; Response Evaluation Criteria in Solid Tumors; Retroperitoneal Neoplasms; Soft Tissue Neoplasms; Thoracic Neoplasms; Thoracic Wall; Treatment Outcome; Young Adult | 2017 |
8 other study(ies) available for imatinib mesylate and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Giant Cell Tumor of Tendon Sheath; Humans; Imatinib Mesylate; Indazoles; Pyrimidines; Radiotherapy, Adjuvant; Sarcoma; Soft Tissue Neoplasms; Sulfonamides | 2020 |
Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation.
Topics: Adult; Aged; Antineoplastic Agents; Cell Transformation, Neoplastic; Dermatofibrosarcoma; Disease-Free Survival; Extremities; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Skin Neoplasms; Soft Tissue Neoplasms; Torso; Treatment Outcome; Young Adult | 2017 |
[Chordoma cutis, an unusual clinical presentation of a rare neoplasm: Chordoma].
Topics: Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Chordoma; Combined Modality Therapy; Contraindications, Procedure; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Paraplegia; Radiotherapy, Adjuvant; Sacrococcygeal Region; Skin Neoplasms; Skin Ulcer; Soft Tissue Neoplasms | 2018 |
[Updates on pathology of soft tissue tumors].
Topics: Antineoplastic Agents; Benzamides; Biopsy, Large-Core Needle; Drug Delivery Systems; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Soft Tissue Neoplasms | 2013 |
Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Bone Neoplasms; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Sarcoma; Smoking; Soft Tissue Neoplasms | 2008 |
Subcutaneous metastasis of a GIST tumour unresponsive to Imatinib.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Electrocoagulation; Esophageal Neoplasms; Esophagectomy; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Pyrimidines; Soft Tissue Neoplasms; Subcutaneous Tissue; Surgical Flaps | 2011 |
Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Immunoassay; Piperazines; Platelet Count; Prospective Studies; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Vascular Endothelial Growth Factor A | 2004 |
Systemic therapy for advanced soft-tissue sarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Doxorubicin; Gastrointestinal Neoplasms; Humans; Ifosfamide; Imatinib Mesylate; Piperazines; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Survival Rate | 2002 |